Sector News

Drugmakers omit detail on FDA drug rejections, study finds

June 15, 2015
Life sciences
Pharmaceutical companies are holding back information from the public on why their medicines have been rejected by the US Food and Drug Administration, a study published in the BMJ has found.
 
An analysis of 61 FDA complete response letters sent out between August 2008 and June 2013 has revealed that the information released by drugmakers on the reasons for refusal only fully matched the regulator’s actual issues in 14% of cases. 
 
The researchers also found that in 21% there was no concordance between the CRL and the company’s press release at all, while nearly a fifth (18%) of CRLs weren’t even reported on. And only 59% of pharmas reported the need for extra clinical trials if they had been requested by the CRL, while of seven CRLs reporting higher mortality rates in treated participants only one associated press release reported this fact.
 
The researchers conclude that there are substantial differences in content between confidential CRLs and the information issued by sponsors, and so press releases “are generally an incomplete source of reasons for FDA non-approval of applications”.
 
CRLs are currently confidential, but campaigners have long argued that the US regulator should fully disclose this information, as occurs across the pond in Europe. The potential benefits of this would include “better informing the development of new drugs, facilitating a richer public health discourse, and counteracting misconceptions regarding FDA’s reasons for denial of applications,” the researchers argue.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach